Glaukos Corp (Glaukos) is an ophthalmic medical device company that develops micro technologies to improve glaucoma therapy. The company develops injectable micro-scale therapies to address the complete range of glaucoma disease states and progression. It provides products such as micro stent devices to treat glaucoma such as iStent trabecular micro-bypass stent for the treatment of mild- to moderate-open-angle glaucoma. Glaukos’ iStent is used in conjunction with cataract surgery. Glauko’s iStent improves outflow by creating a patent bypass between the anterior chamber and Schlemm’s canal. The company markets its products through a network of distributors in Germany, Canada, the UK, Australia, Brazil and Japan, among others. Glaukos is headquartered in San Clemente, California, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
The report analyzes all pipeline products in development for the company Glaukos Corp
The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
The report provides detailed description of products in development, technical specification and functions
The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
To formulate effective Research & Development strategies
Develop market-entry and market expansion strategies
Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note:Some sections may be missing if data is unavailable for the company
Glaukos Corp Company Overview
Glaukos Corp Company Snapshot
Glaukos Corp Pipeline Products and Ongoing Clinical Trials Overview
Glaukos Corp – Pipeline Analysis Overview
Glaukos Corp - Key Facts
Glaukos Corp - Major Products and Services
Glaukos Corp Pipeline Products by Development Stage
Glaukos Corp Ongoing Clinical Trials by Trial Status
Glaukos Corp Pipeline Products Overview
Brillouin Scanning Microscope
Brillouin Scanning Microscope Product Overview
iDose Rock
iDose Rock Product Overview
iDose TREX
iDose TREX Product Overview
IOP Sensor System
IOP Sensor System Product Overview
iStent Infinite Trabecular Micro-Bypass System
iStent Infinite Trabecular Micro-Bypass System Product Overview
iStent Infinite Trabecular Micro-Bypass System Clinical Trial
Mosaic System - Presbyopia
Mosaic System - Presbyopia Product Overview
Oxygen Enrichment Device
Oxygen Enrichment Device Product Overview
Glaukos Corp - Key Competitors
Glaukos Corp - Key Employees
Glaukos Corp - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Glaukos Corp, Recent Developments
Jun 14, 2024: Glaukos Announces Agreements to Exchange $230 Million in Principal Amount of Its 2.75% Convertible Senior Notes Due 2027 for Common Stock
May 28, 2024: Wilmington Eye Now Offering iDose TR as a New Treatment Option to Reduce Eye Pressure in Patients With Ocular Hypertension and Open-Angle Glaucoma
Apr 01, 2024: Glaukos To Present Numerous Scientific Abstracts at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting
Mar 26, 2024: Center For Sight Implants New FDA-Approved iDoseTR Device
Feb 29, 2024: Celanese Announces Commercial Launch of Glaukos' iDose TR (Travoprost Intracameral Implant) Using Celanese's VitalDose Ethylene Vinyl Acetate (EVA)
Dec 20, 2023: Glaukos Announces Participation in the J.P. Morgan Healthcare Conference
Dec 14, 2023: Glaukos Announces FDA Approval of iDose TR (Travoprost Intracameral Implant)
Oct 31, 2023: Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2023 American Academy of Ophthalmology Annual Meeting
May 01, 2023: Glaukos Technologies featured in numerous scientific abstracts at the 2023 American Society of Cataract and Refractive Surgery Annual Meeting
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer
List of Tables
Glaukos Corp Pipeline Products and Ongoing Clinical Trials Overview
Glaukos Corp Pipeline Products by Equipment Type
Glaukos Corp Pipeline Products by Indication
Glaukos Corp Ongoing Clinical Trials by Trial Status
Glaukos Corp, Key Facts
Glaukos Corp, Major Products and Services
Glaukos Corp Number of Pipeline Products by Development Stage
Glaukos Corp Pipeline Products Summary by Development Stage
Glaukos Corp Ongoing Clinical Trials by Trial Status
iStent Infinite Trabecular Micro-Bypass System - Product Status
iStent Infinite Trabecular Micro-Bypass System - Product Description
iStent Infinite Trabecular Micro-Bypass System - A Prospective, Multicenter Study of the Glaukos iStent Infinite Trabecular Micro-Bypass System Model iS3 in Subjects with Mild to Moderate Primary Open-angle Glaucoma
iStent Infinite Trabecular Micro-Bypass System - A Prospective, Randomized, Controlled, Comparative Multicenter Clinical Study of Glaukos Trabecular Micro-Bypass System Model iS3 Infinite Vs. Hydrus in Adult Subjects with Primary Open-Angle Glaucoma (POAG)
Mosaic System - Presbyopia - Product Status
Mosaic System - Presbyopia - Product Description
Oxygen Enrichment Device - Product Status
Oxygen Enrichment Device - Product Description
Glaukos Corp, Key Employees
Glaukos Corp, Subsidiaries
Glossary
List of Figures
Glaukos Corp Pipeline Products by Equipment Type
Glaukos Corp Pipeline Products by Development Stage
Glaukos Corp Ongoing Clinical Trials by Trial Status